Eculizumab in aHUS not responding to PEX (n = 17)
| . | Demographic and laboratory data . | Week 26 . | Week 64 . |
|---|---|---|---|
| Data at presentation | |||
| Median age, y | 28 (17-68) | ||
| Median platelets, ×109/L | 118 (62-161) | ||
| Median creatinine, mg/dL | 2.9 (1.4-8.9) | ||
| LDH (>ULN) | 10/17 (59) | ||
| Response criteria | |||
| Normalized platelet count | 13/15 (87)* | 13/15 (87)* | |
| Decreased creatinine by 25% | 11/17 (65)† | 13/17 (76)† | |
| Increased est. GFR ≥ 15 mL/min/1.73m2 | 8/17 (47) | 9/17 (53) |
| . | Demographic and laboratory data . | Week 26 . | Week 64 . |
|---|---|---|---|
| Data at presentation | |||
| Median age, y | 28 (17-68) | ||
| Median platelets, ×109/L | 118 (62-161) | ||
| Median creatinine, mg/dL | 2.9 (1.4-8.9) | ||
| LDH (>ULN) | 10/17 (59) | ||
| Response criteria | |||
| Normalized platelet count | 13/15 (87)* | 13/15 (87)* | |
| Decreased creatinine by 25% | 11/17 (65)† | 13/17 (76)† | |
| Increased est. GFR ≥ 15 mL/min/1.73m2 | 8/17 (47) | 9/17 (53) |
The clinical data both at presentation and after therapy with eculizumab are presented for the 17 patients enrolled in the prospective study of eculizumab in patients with a progressive TMA after PEX therapy. Fifteen patients completed 26 weeks of therapy, with 13 patients continuing therapy beyond 26 weeks, and were available for follow-up after a median of 64 weeks of therapy.
GFR, glomerular filtration rate; ULN, upper limit of normal.
Two patients with normal platelet count at start of therapy not evaluable.
Four of 5 patients able to become independent of the need for dialysis after therapy.